Pharma Jonpi . / 1.1 / .: (The) Lurbinectedin/Doxorubicin Combination Syowed Remarkable Activity (in the) Second-Line Setting in SCLC, Especially in Sensitive Patients,” The Researchers Wrote.

13 febrero 2019

(The) Lurbinectedin/Doxorubicin Combination Syowed Remarkable Activity (in the) Second-Line Setting in SCLC, Especially in Sensitive Patients,” The Researchers Wrote.

Zepsyre es el Principal Candidato Potencial que se Vislumbra como posible Tratamiento del Cáncer de Pulmón Microcítico en Segunda Línea . By Jack West .